MarketFriction

Elder Project Ltd

BSE 524788 · Pharmaceuticals
Market cap₹Cr.
Not trading

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Mar 2013Jun 2013Sep 2013Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015
Revenue from operations0.910.520.010.430.580.240.981.020.19
Operating costs0.141.090.470.520.710.570.730.840.45
EBITDA0.77-0.57-0.46-0.09-0.13-0.330.250.18-0.26
EBITDA margin %84.62%-109.62%-4,600.00%-20.93%-22.41%-137.50%25.51%17.65%-136.84%
Depreciation & amortisation0.140.080.130.130.130.130.130.130.13
Finance costs0.860.790.960.980.951.400.740.740.72
Non-operating income-0.411.320.280.280.270.640.350.320.32
Pre-tax profit-0.64-0.12-1.27-0.92-0.94-1.22-0.27-0.37-0.79
Effective tax rate %-23.44%50.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Profit after tax-0.50-0.18-1.27-0.92-0.93-1.22-0.27-0.36-0.79
Earnings per share (Rs)-1.55-0.56-3.93-2.85-2.88-3.77-0.84-1.11-2.44
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Jun 2013 15mTTM
Revenue from operations11.723.104.885.626.848.629.716.392.43
Operating costs11.583.394.665.045.536.377.524.922.59
EBITDA0.14-0.290.220.581.312.252.191.47-0.16
EBITDA margin %1.19%-9.35%4.51%10.32%19.15%26.10%22.55%23.00%-6.58%
Depreciation & amortisation0.370.400.530.540.550.580.600.600.52
Finance costs1.481.701.603.671.962.262.802.683.60
Non-operating income4.060.820.992.210.540.631.511.531.63
Pre-tax profit2.35-1.57-0.92-1.42-0.660.040.30-0.28-2.65
Effective tax rate %7.66%-36.94%-66.30%16.90%-1.52%175.00%83.33%25.00%
Profit after tax2.17-0.99-0.31-1.66-0.65-0.030.06-0.34-2.64
Earnings per share (Rs)6.71-3.06-0.96-5.13-2.01-0.090.19-1.05-8.16
Paid out as dividend %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Revenue CAGR%6%-2%58%
Profit CAGR%-20%6%28%
Share price CAGR%%%%
Average return on equity%-26%-11%-29%
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Jun 2013
Net block (property, plant)5.066.156.716.406.026.256.094.43
Capital work in progress0.000.670.000.000.000.000.000.00
Investments7.337.347.347.347.347.347.347.39
Current & other assets11.3814.7530.0218.978.488.4711.2912.74
Total assets23.7728.9144.0732.7121.8422.0624.7224.56
Share capital3.233.233.233.233.233.233.233.23
Reserves & surplus2.321.331.02-0.64-1.29-1.32-1.27-1.61
Total debt15.2021.3635.3528.1715.6418.7220.9620.03
Other liabilities & provisions3.022.994.471.954.261.431.802.91
Equity + liabilities23.7728.9144.0732.7121.8422.0624.7224.56
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Jun 2013
Operating cash flow-0.27-9.14-10.8116.244.529.242.951.51
Investing cash flow0.67-1.99-0.03-0.060.36-0.58-1.080.95
Free cash flow (after capex)-0.60-11.30-11.2316.014.348.482.522.46
Financing cash flow-0.3311.1812.99-8.79-14.49-8.69-1.75-2.68
Net change in cash0.070.052.157.39-9.61-0.030.12-0.22
Cash conversion (OCF / EBITDA) %-193%3,152%-4,914%2,800%348%412%135%103%
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Jun 2013
Return on capital employed %0.56%2.08%6.40%5.38%12.14%13.46%9.96%
Receivable days70.3850.6311.9714.9413.3434.3086.4627.99
Inventory days20.38691.58189.80192.75180.66149.59150.94
Payable days129.461,460.00428.27463.43412.93329.10359.51
Cash cycle (days)-38.70-717.79-226.50-255.74-218.93-145.21-122.1127.99
Working capital days245.721,256.311,626.05382.54143.0121.1784.9584.54

Fundamentals

Market value₹ Cr.
Last price₹ 20.2
Book value / share₹ -11.4
Return on capital9.96 %
Return on equity-29.0 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)58%
Profit CAGR (TTM)28%
Standalone figures.
Valuation
P/B, 3-year average5.57x
P/B, 5-year average4.92x
Profitability
Operating margin (excl. other income)26.10%
Operating margin (incl. other income)33.41%
EBITDA margin54.96%
Pre-tax margin-99.29%
Net profit margin-98.58%
Net margin, latest quarter-35.29%
ROE-1.56%
ROCE12.04%
ROA-0.14%
ROE, 3-year average-26.26%
ROCE, 3-year average7.94%
ROA, 3-year average-2.28%
ROE, 5-year average-21.08%
ROCE, 5-year average5.29%
ROA, 5-year average-2.29%
ROIC (approx.)-3.78%
Tax rate175.00%
Other income / net worth32.98%
Growth
Sales growth (latest year)26.02%
Sales CAGR, 3 years20.88%
Sales CAGR, 5 years-5.96%
Sales growth QoQ4.08%
Sales growth YoY (latest quarter)137.21%
Per share
EPS (TTM)Rs -8.60
EPS (latest year)Rs -0.09
EPS (latest quarter)Rs -1.11
EPS, 3-year averageRs -2.41
EPS, 5-year averageRs -2.25
Book value per shareRs 5.91
Sales per shareRs 8.72
Cash flow per shareRs 28.58
Efficiency
Asset turnover0.39x
Fixed asset turnover1.38x
Inventory turnover7.72x
Inventory days47 days
Debtor days34 days
Debtors turnover10.64x
Leverage
Total debtRs 19 Cr
Cash and bankRs 0 Cr
Net debtRs 19 Cr
Debt to equity9.80x
Net debt / EBITDA11.96x
Interest coverage0.27x
Owners' fund to total sources8.66%
Debt to assets84.86%
Cash flow
Operating cash flow (latest year)Rs 9 Cr
Investing cash flow (latest year)Rs -1 Cr
Financing cash flow (latest year)Rs -9 Cr
Net change in cash (latest year)Rs -0 Cr
Sales to cash flow0.93x
Statement figures
Net sales (TTM)Rs 3 Cr
Net sales (latest year)Rs 9 Cr
Sales (latest quarter)Rs 1 Cr
Operating profit excl. other income (latest year)Rs 2 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 2 Cr
PBDT (TTM)Rs -2 Cr
Profit before tax (TTM)Rs -3 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -3 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -0 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 4 Cr
Total expenditure (latest year)Rs 6 Cr
Total income (latest year)Rs 9 Cr
Share capitalRs 3 Cr
ReservesRs -1 Cr
Shareholders' fundsRs 2 Cr
Total assetsRs 22 Cr
Net blockRs 6 Cr
InvestmentsRs 7 Cr
ReceivablesRs 1 Cr
InventoryRs 0 Cr
Other liabilitiesRs 1 Cr
Shares outstanding (crore)0.32
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.

Red flags

F-score 6 of 8
lookProfit leans on other income Other income was 1575% of pre-tax profit in 2013
lookRepeated losses Net loss in each of the last two years
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Mar 2015
Sales ₹0 Cr -67.2% vs Mar 2014. Net loss ₹1 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Elder Project Ltd?

Elder Project Ltd (524788) has a market capitalisation of Rs Cr. at the close.

What were Elder Project Ltd's latest quarterly results?

In the Mar 2015 quarter, Elder Project Ltd sales was Rs 0 Cr (-67.2% vs Mar 2014) with a net loss of Rs 1 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03